Collectively, our data identify a novel IFN-γ-STAT1-MDK signalling axis (Figure 7), which confers the pro-metastatic adverse effect of IFN-γ in immunotherapy, whereas targeting MDK may efficiently abrogate IFN-γ-elicited cancer metastasis. Here, STAT1 is linked to cancer.